https://scholars.lib.ntu.edu.tw/handle/123456789/568743
標題: | Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy | 作者: | Lin C.-L. Liao L.-Y. Wang C.-S. PEI-JER CHEN Lai M.-Y. DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2004 | 出版社: | Blackwell Publishing Ltd | 卷: | 24 | 期: | 1 | 起(迄)頁: | 9-15 | 來源出版物: | Liver International | 摘要: | Aim: Lamivudine is effective in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, but the relapse rate after cessation of treatment is high. The evolution of viral genome may contribute to the viral replication under antiviral pressure of lamivudine. We therefore determined the evolution of hepatitis B virus (HBV) precore/basal core promoter and polymerase genes in HBeAg-positive chronic hepatitis B patient during lamivudine therapy. Method: Thirteen patients with HBeAg-positive chronic hepatitis who had received short-term lamivudine therapy (mean, 30 weeks) during 1999-2001 were enrolled. The precore/basal core promoter region and polymerase gene were amplified and directly sequenced before, during and post lamivudine treatment. Result: HBeAg loss or seroconversion occurred in 11, but eight relapsed after stopping therapy and five had reversion of HBeAg. Before treatment, basal core promoter mutation was found in 1. In the first 3 months of therapy, a rapid decline of serum HBV DNA level accompanied with basal core promoter mutation appeared in 11 of 13 patients (vs. before therapy; P = 0.003). However, this mutant was replaced by wild-type virus in four of eight patients who relapsed after treatment. There was no significant change of precore sequences before and during therapy. Conclusions: Lamivudine therapy may result in the rapid development of basal core promoter mutation of HBV, but this mutation may revert to wild type gradually after cessation of therapy. Copyright ? Blackwell Munksgaard, 2004. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984539156&doi=10.1111%2fj.1478-3231.2004.00893.x&partnerID=40&md5=89fa084348539930b88600beedd57f45 https://scholars.lib.ntu.edu.tw/handle/123456789/568743 |
ISSN: | 1478-3223 | DOI: | 10.1111/j.1478-3231.2004.00893.x | SDG/關鍵字: | DNA polymerase; hepatitis B core antigen; hepatitis E antigen; lamivudine; article; clinical article; controlled study; drug response; female; gene amplification; gene mutation; gene sequence; hepatitis B; human; male; molecular evolution; nonhuman; promoter region; recurrence risk; reversal reaction; seroconversion; short course therapy; virus mutant; virus replication; wild type |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。